Kenvue Inc. (NYSE:KVUE) Receives Average Recommendation of “Hold” from Analysts

Kenvue Inc. (NYSE:KVUE) has received an average recommendation of “Hold” from the thirteen analysts that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $24.3750.

A number of equities research analysts recently weighed in on the stock. Zacks Research raised shares of Kenvue to a “strong sell” rating in a research note on Monday, August 11th. Canaccord Genuity Group dropped their price target on shares of Kenvue from $29.00 to $26.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Royal Bank Of Canada dropped their price target on shares of Kenvue from $24.00 to $22.00 and set a “sector perform” rating for the company in a research note on Friday, August 8th. Citigroup dropped their price target on shares of Kenvue from $24.50 to $22.00 and set a “neutral” rating for the company in a research note on Tuesday, July 15th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Kenvue from $27.00 to $26.00 and set an “overweight” rating for the company in a research note on Friday, July 25th.

Kenvue Trading Up 0.9%

Shares of NYSE KVUE opened at $20.72 on Monday. Kenvue has a 1-year low of $19.75 and a 1-year high of $25.17. The company has a market cap of $39.76 billion, a PE ratio of 27.99, a P/E/G ratio of 2.97 and a beta of 0.83. The company has a current ratio of 0.98, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66. The company has a 50-day moving average of $21.46 and a two-hundred day moving average of $22.45.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, August 7th. The company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.01. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The company had revenue of $3.84 billion during the quarter, compared to the consensus estimate of $3.94 billion. During the same period in the previous year, the firm posted $0.32 earnings per share. The company’s revenue was down 4.0% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, equities analysts expect that Kenvue will post 1.14 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th were paid a dividend of $0.2075 per share. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.0%. This is a positive change from Kenvue’s previous quarterly dividend of $0.21. The ex-dividend date of this dividend was Wednesday, August 13th. Kenvue’s payout ratio is presently 112.16%.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Cambridge Investment Research Advisors Inc. grew its holdings in Kenvue by 4.0% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 106,140 shares of the company’s stock valued at $2,545,000 after purchasing an additional 4,034 shares during the period. IFP Advisors Inc boosted its holdings in shares of Kenvue by 25.3% in the first quarter. IFP Advisors Inc now owns 15,278 shares of the company’s stock valued at $369,000 after buying an additional 3,081 shares during the period. Starboard Value LP acquired a new position in shares of Kenvue in the fourth quarter valued at approximately $467,864,000. Kingswood Wealth Advisors LLC acquired a new position in shares of Kenvue in the first quarter valued at approximately $413,000. Finally, Cooper Investors PTY Ltd. boosted its holdings in shares of Kenvue by 39.7% in the first quarter. Cooper Investors PTY Ltd. now owns 858,076 shares of the company’s stock valued at $20,577,000 after buying an additional 244,043 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.